Vol 71, No 7 (2013)
Original articles
Published online: 2013-07-17

open access

Page views 1145
Article views/downloads 1564
Get Citation

Connect on Social Media

Connect on Social Media

The effect of the renin–angiotensin–aldosterone system inhibition on myocardial function in early and late phases of dilated cardiomyopathy in Tgaq*44 mice

Mirosław Woźniak, Urszula Tyrankiewicz, Łukasz Drelicharz, Tomasz Skórka, Magdalena Jabłońska, Sylwia Heinze-Paluchowska, Stefan Chłopicki
Kardiol Pol 2013;71(7):730-737.

Abstract

Background: The renin–angiotensin–aldosterone system (RAAS) determines progression of heart failure (HF) in humans, and
RAAS inhibition is a major therapeutic strategy in HF.

Aim: To assess the effect of angiotensin-converting enzyme inhibitor (ACE-I) and aldosterone receptor antagonist (ARA) therapy
on the development of HF at its early and late stage in a murine model of dilated cardiomyopathy (Tgaq*44 mice).

Methods: Tgaq*44 mice at the early or advanced stage of HF received combined therapy including ACE-I (perindopril
2 mg/kg) and ARA (canrenone 20 mg/kg). Cardiac function was assessed by magnetic resonance imaging before and after
2 months of treatment.

Results: Combined therapy with perindopril and canrenone resulted in preserved systolic function at the early stage and
reduced chamber dilatation at the advanced stage of HF in Tgaq*44 mice.

Conclusions: Activation of the RAAS is involved in progression of HF in Tgaq*44 mice with dilated cardiomyopathy. Therapeutic
efficacy of ACE-I and ARA to inhibit systolic dysfunction and cardiac chamber dilation depends on the stage of HF development.

Article available in PDF format

View PDF Download PDF file